Editas Medicine, Cambridge, Massachusetts, USA.
Tessera Therapeutic, Cambridge, Massachusetts, USA.
CRISPR J. 2020 Jun;3(3):177-187. doi: 10.1089/crispr.2019.0074.
Multiplexed genome editing with DNA endonucleases has broad application, including for cellular therapies, but chromosomal translocations, natural byproducts of inducing simultaneous genomic breaks, have not been explored in detail. Here we apply various CRISPR-Cas nucleases to edit the T cell receptor alpha and beta 2 microglobulin genes in human primary T cells and comprehensively evaluate the frequency and stability of the resulting translocations. A thorough translocation frequency analysis using three orthogonal methods (droplet digital PCR, unidirectional sequencing, and metaphase fluorescence hybridization) yielded comparable results and an overall translocation rate of ∼7% between two simultaneous CRISPR-Cas9 induced edits. In addition, we show that chromosomal translocations can be reduced when using different nuclease combinations, or by the presence of a homologous single stranded oligo donor for multiplexed genome editing. Importantly, the two different approaches for translocation reduction are compatible with cell therapy applications.
利用 DNA 内切酶进行多重基因组编辑具有广泛的应用,包括细胞治疗,但诱导同时发生基因组断裂的自然副产物染色体易位尚未得到详细研究。在这里,我们应用各种 CRISPR-Cas 核酸酶来编辑人原代 T 细胞中的 T 细胞受体 alpha 和 beta 2 微球蛋白基因,并全面评估由此产生的易位的频率和稳定性。使用三种正交方法(液滴数字 PCR、单向测序和中期荧光杂交)进行彻底的易位频率分析,得到了可比的结果,两个同时进行的 CRISPR-Cas9 诱导编辑之间的总易位率约为 7%。此外,我们表明,当使用不同的核酸酶组合或存在同源单链寡核苷酸供体进行多重基因组编辑时,染色体易位的频率可以降低。重要的是,两种降低易位的方法都与细胞治疗应用兼容。